Early Prevention of Obesity: Tackling from Conception

By Melike Belenli Gümüş

October 16, 2024

A recent article discusses the potential for monitoring obesity from the earliest stages of development, including during the fetal period in the womb. This proactive approach highlights the importance of addressing obesity right from conception in order to achieve early prevention of obesity.

Early Prevention of Obesity

The article highlights research focused on the early prevention of obesity through a project named “eprObes” (Early Prevention of Obesity). This initiative aims to implement interventions that could significantly lower the risk of obesity later in life.

Factors Influencing Obesity

The study aims to identify and understand the various factors that contribute to obesity, starting from the pre-conception period and continuing through pregnancy and early childhood. These factors include genetic, environmental, and lifestyle influences that can affect the development of obesity in children.

Importance of Prenatal Care

The research emphasises the critical role of prenatal care in monitoring both the mother’s and the fetus’s health. Preventive measures during pregnancy could be key in reducing the incidence of obesity later in life.

Long-Term Health Implications

By addressing obesity at its earliest roots, the study aims to lower the risk of long-term health complications associated with obesity, such as metabolic syndrome, diabetes, and other related health issues.

Overall, the article indicates a shift towards a more proactive and preventive approach to managing obesity, starting at the earliest possible stage of human development. This new focus could lead to healthier outcomes for future generations.

Reference url

Recent Posts

Oral Semaglutide Benefits: EMA Approves First Oral GLP-1 RA with Cardiovascular Perks

By HEOR Staff Writer

September 16, 2025

Novo Nordisk’s oral semaglutide (Rybelsus®) has received a significant label update from the European Medicines Agency (EMA). It is now the first and only oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved in the EU for type 2 diabetes with proven cardiovascular benefits. This deci...
New Federal Actions to Combat Misleading Prescription Drug Ads in 2025

By João L. Carapinha

September 11, 2025

Misleading prescription drug ads have become a pressing concern in the United States, prompting decisive federal action. What are the new measures targeting deceptive pharmaceutical advertising, and how will these changes affect public health and healthcare costs? In September 2025, a
Ending Unproven Fertility Treatments: NICE Calls for Evidence-Based Care in Clinics

By João L. Carapinha

September 10, 2025

Unproven fertility treatments—a term referring to add-on procedures without robust clinical evidence—have come under renewed scrutiny in the UK. Many prospective parents want to know: Why are unproven fertility treatments being discouraged, and what does this mean for fertility clinic choices...